Abstract 【Objective】To explore the effect of venlafaxine combined with levodopa treatment on the psychological state and motor function of patients with Parkinson's disease accompanied by depression. 【Methods】Ninety-eight Parkinson's disease patients with depression were randomly divided into the observation group and the control group, with 49 patients in each group. The control group received oral levodopa treatment, while the observation group additionally received venlafaxine hydrochloride extended-release capsules. Before the treatment and after 8 weeks of treatment, the psychological state [Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD-24)], motor function [Part Ⅲ of the Unified Parkinson's Disease Rating Scale (UPDRS Ⅲ), Timed Up and Go Test (TUGT), Berg Balance Scale (BBS)], inflammatory factors [serum interleukin-2 (IL-2), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP)], quality of life [Parkinson's Disease Questionnaire (PDQ-39), WHO Quality of Life-BREF (QOL)] were compared between the two groups, as well as the incidence of adverse reactions.【Results】 After treatment, scores of HAMA and HAMD-24 in both groups were significantly lower than before treatment (P<0.05), with the observation group scoring lower than the control group (P<0.05). UPDRS Ⅲ and TUGT scores decreased, while BBS scores increased post-treatment compared to pre-treatment (P<0.05), with the observation group performing better than the control group (P<0.05). IL-2, TNF-α, and CRP levels decreased after treatment in both groups (P<0.05), with lower levels in the observation group (P<0.05). PDQ-39 scores decreased and QOL scores increased post-treatment compared to pre-treatment in both groups (P<0.05), with the observation group performing better (P<0.05). The overall incidence of adverse reactions was similar between the groups (P>0.05).【Conclusion】 Venlafaxine combined with levodopa can effectively improve the depressive state, enhance motor function, and improve the quality of life of patients with Parkinson's disease and depression, warranting further clinical application.
BI Zongqin,WANG Jia. The Effect of Venlafaxine Combined with Levodopa on the Psychological State and Motor Function of Parkinson's Disease Patients with Depression[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(9): 1388-1391.
[1] BLOEM B R, OKUN M S, KLEIN C.Parkinson's disease[J].Lancet,2021,397 (10291):2284-2303. [2] PAJARES M, I ROJO A, MANDA G, et al. Inflammation in parkinson's disease:mechanisms and therapeutic implications[J].Cells,2020,9(7):1687. [3] 姬利,韩霞,张亚峰,等.美多芭联合普拉克索治疗帕金森病的疗效及对患者运动功能、血清同型半胱氨酸和血尿酸水平的影响[J].海南医学,2022,33(10):1241-1244. [4] CARBONI L, MCCARTHY D J, DELAFONT B,et al. Biomarkers for response in major depression:comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies.[J].Transl Psychiatry,2019,9(1):182. [5] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业.中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016,49(4):268-271. [6] 李凌江,马辛.中国抑郁障碍防治指南[M].北京:中华医学电子音像出版社,2015:5. [7] 刘京,刘得水,荣华,等.帕金森病中医药研究进展[J].中国老年学杂志,2022,42(19):4878-4881. [8] PAJARES M, I ROJO A, MANDA G,et al. Inflammation in parkinson's disease:mechanisms and therapeutic implications[J].Cells,2020,9(7):1687. [9] LISSEMORE J I, MULSANT B H, RAJJI T K, et al. Cortical inhibition, facilitation and plasticity in late-life depression:effects of venlafaxine pharmacotherapy[J].Psychiatry Neurosci,2021,46(1):E88-E96. [10] FURUKAWA T A, CIPRIANI A, COWEN P J, et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression:a systematic review and dose-response meta-analysis[J].Lancet Psychiatry,2019, 6(7):601-609. [11] 李珂,洪丽.不同运动障碍分型的帕金森病伴抑郁患者的联合治疗比较[J].广州医科大学学报,2021,49(5):83-87. [12] 石强,罗琴,龚亲平,等.重复经颅磁刺激联合“氧-针-康”方案对帕金森病患者运动功能以及血清C反应蛋白和血浆多巴胺的影响[J].中国全科医学,2020,23(27):3460-3465. [13] 郭英杰,张晓明,魏丹,等.甜梦口服液联合文拉法辛治疗脾肾阳虚型抑郁症疗效观察[J].中草药,2022,53(4):1117-1120.
[1]
. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(4): 617-619.
2024, Vol. 41 
